Changes in bone mineral density and serum calcium levels after romosozumab treatmet in postmenopausal osteoporosis patients:About short-term results at 6 months

Not Applicable

Recruiting

• Conditions: primary osteoprosis; osteoprosis; D010024

• Registration Number: JPRN-jRCT1040190111
• Lead Sponsor: Kobayakawa Tomonori

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-01-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

1.postmenopausal women with osteoporosis
2.patients who used romosozumab for 6 months

Exclusion Criteria

1.patients who are allergic to romosozumab
2.hypocacemia

Study & Design

• Study Type: Observational
• Study Design: Not specified